论文部分内容阅读
目的探讨KAI1/CD82在肾母细胞瘤转移中的表达及临床意义。方法选取38例确诊为肾母细胞瘤的组织蜡块标本,按有无转移分为两组,采用免疫组织化学的方法检测其KAI1/CD82的表达。结果肾母细胞瘤中无转移组和有淋巴结或远处转移组的KAI1/CD82阳性表达率分别为53.85%、33.33%,两者间的差异有统计学意义;Ⅰ、Ⅱ、Ⅲ、Ⅳ期肾母细胞瘤中KAI1/CD82阳性表达率分别为62.50%、58.33%、33.33%、33.33%,各组间的差异无统计学意义。化疗组与未化疗组间差异均无统计学意义。结论肾母细胞瘤中KAI1/CD82的阳性表达率与肿瘤是否转移有关,与临床分期无关。
Objective To investigate the expression of KAI1 / CD82 in Wilms’ tumor and its clinical significance. Methods Totally 38 specimens of nephroblastoma were collected and divided into two groups according to the presence or absence of metastasis. The expression of KAI1 / CD82 was detected by immunohistochemistry. Results The positive rate of KAI1 / CD82 in non-metastasis group and lymph node or distant metastasis group was 53.85% and 33.33%, respectively. The difference between the two groups was statistically significant. The positive rates of KAI1 / CD82 in stage Ⅰ, Ⅱ, Ⅲ and Ⅳ The positive expression rate of KAI1 / CD82 in Wilms’ tumor was 62.50%, 58.33%, 33.33% and 33.33% respectively. There was no significant difference among the groups. Chemotherapy group and no chemotherapy group differences were not statistically significant. Conclusion The positive rate of KAI1 / CD82 in Wilms’ tumor is related to the metastasis of the tumor, but not to the clinical stage.